Solabegron

CAS: 252920-94-8

Ref. 3D-CKA92094

Produktinformation

• Name: Solabegron
• Synonyme: (-)-(R)-3′-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]biphenyl-3-carboxylic acid, 3′-[[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino][1,1′-biphenyl]-3-carboxylic acid, Gw 427353, [1,1′-Biphenyl]-3-carboxylic acid, 3′-[[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-

Beschreibung

Solabegron is a drug that has clinical relevance for the treatment of bladder disorders. It is an agonist of the beta-3 adrenergic receptor, with no affinity for beta-1 or beta-2 receptors. In animal models, solabegron has been shown to increase detrusor muscle contractility and reduce urinary symptoms. Solabegron also acts as an inhibitor of DPP-IV, which is involved in the breakdown of glucagon-like peptide (GLP). The drug reduces body mass index and improves metabolic disorders in animals by stimulating GLP secretion. Solabegron is metabolized by CYP3A4 and has hydrogen bonding interactions with drugs such as erythromycin, clarithromycin, and telithromycin.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 410.89 g/mol
• Formel: C₂₃H₂₃ClN₂O₃
• Reinheit: Min. 95%